Hikma Pharmaceuticals (HIK)

 

HIK Share PerformanceMore

52 week high2,346.0 16/03/17
52 week low906.5 14/11/17
52 week change -620.0 (-37.26%)
4 week volume21,615,463 25/10/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Holding(s) in Company

RNS Number: 9563W Hikma Pharmaceuticals Plc 20 November 2017 TR-1: S tandard form for notification of major holdings LONDON, 20 November 2017 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK) (LEI: 549300BNS685UXH4JI75) , the fast-growing multinational pharmaceuticals group, announces as follows: NOTIFICATION OF MAJOR HO...

Broker Forecast - Peel Hunt issues a broker note on Hikma Pharmaceuticals PLC

Peel Hunt today reaffirms its hold investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and set its price target at...

Holding(s) in Company

RNS Number: 4246W Hikma Pharmaceuticals Plc 14 November 2017 TR-1: S tandard form for notification of major holdings LONDON, 14 November 2017 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK) (LEI: 549300BNS685UXH4JI75) , the fast-growing multinational pharmaceuticals group, announces as per the attached: NOTIFICATION OF MA...

Hikma Acquires Products from Boehringer Ingelheim

RNS Number: 3688W Hikma Pharmaceuticals Plc 14 November 2017 PRESS RELEASE Hikma acquires products in Europe from Boehringer Ingelheim London, 14 November 2017 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the multinational pharmaceutical group, announ...

Broker Forecast - JP Morgan Cazenove issues a broker note on Hikma Pharmaceuticals PLC

JP Morgan Cazenove today reaffirms its neutral investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut it...

Broker Forecast - HSBC issues a broker note on Hikma Pharmaceuticals PLC

HSBC today reaffirms its reduce investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut its price target to ...

Time to buy bombed-out Hikma Pharmaceuticals?

They've been through the mill this year, losing almost 60% of their value, but Graeme Evans has found an expert backing...

Broker Forecast - Numis issues a broker note on Hikma Pharmaceuticals PLC

Numis today upgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to buy (from add) and set its pric...

Fundamental DataMore

P/E ratio15.699
EPS66.5
Dividend yield3.161 %

Latest discussion posts More

  • Re: P/E 10; strong balance sheet

    We all know the market is incredibly rogue, corrupt and a short sellers dream. BTW how many of you have notified the FCA's market abuse and intelligence teams regarding this ...
    14-Nov-2017
    Thedarkkn1ght
  • Re: P/E 10; strong balance sheet

    I thought this morning's news was positive, and a broker update had a target price about 50% up from here, but when the market is out of love with a share.......
    14-Nov-2017
    Hardboy
  • P/E 10; strong balance sheet

    Trading on a P/E of just 10 now Agree with most of the comments on here that the fall is absurd and way overdone. Great assets and balance sheet. Global ...
    14-Nov-2017
    Thedarkkn1ght

Users' HoldingsMore

Users who hold Hikma Pharmaceuticals also hold..
LLOYDS GRP.36%
GLAXOSMITHKLINE32%
BT GROUP25%
BP24%
RDS 'B'23%

Codes & Symbols

ISINGB00B0LCW083
SymbolsHIK, LSE:HIK, HIK.L, HIK:LN, LON:HIK, XLON:HIK

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account